Form 4: Orchestra BioMed Executive's Tax Withholding on RSU Vesting

Orchestra BioMed Holdings, Inc. reports President and COO Darren Sherman's tax-related share withholding following restricted stock unit vesting.

Summary

• Darren Sherman, President and Chief Operating Officer, and a Director of Orchestra BioMed Holdings, Inc. (OBIO), reported a transaction on November 25, 2025.
• The transaction involved the disposition of 40,340 shares of Common Stock, par value $0.0001 per share, at a price of $5.35 per share.
• This disposition represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• No shares were sold in the open market as a result of this transaction.
• Following this transaction, Darren Sherman beneficially owns 846,157 shares of Common Stock directly.

Sentiment

Score: 7

Explanation: The filing reports a routine, non-market disposition of shares for tax purposes related to RSU vesting. This is a neutral to slightly positive event as it confirms RSU vesting and the executive's continued significant ownership, with no actual market sale.

Positives

• The transaction is a routine tax withholding event, not a market sale by the executive, indicating continued holding of vested shares.
• The vesting of restricted stock units suggests the executive is meeting performance or tenure requirements.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units.
• No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations.

Industry Context

This filing is a standard insider transaction report (Form 4) detailing an executive's share activity. It does not provide broader industry context but is a routine disclosure for publicly traded companies regarding executive compensation and ownership.

Comparison to Industry Standards

• This is a routine Form 4 filing for tax withholding upon RSU vesting, a common practice across all industries for executive compensation. It does not present results that can be compared to specific industry benchmarks or competitor performance.

Stakeholder Impact

• Shareholders: The filing indicates a routine administrative transaction related to executive compensation, with no direct impact on company operations or strategy. It confirms an executive's continued beneficial ownership.
• Employees: No direct impact on employees beyond the reporting person.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing, which is a historical report of a completed transaction.

Key Dates

Recommendation

This Form 4 filing details a routine, non-market disposition of shares by an executive to cover tax obligations upon the vesting of restricted stock units. It does not indicate any change in the company's fundamentals, strategic direction, or the executive's confidence in the company beyond the standard compensation structure. Therefore, it provides no new information to warrant a change in investment recommendation; a 'hold' position is maintained based solely on this filing.

Keywords

Orchestra BioMed Holdings, OBIO, Darren Sherman, Form 4, SEC filing, insider transaction, restricted stock units, RSU vesting, tax withholding, beneficial ownership